Amyloid light chain (AL) amyloidosis is among the more common and more severe of the
amyloidoses usually involving the slow proliferation of a bone-marrow-residing plasma cell …

In amyloid light chain (AL) amyloidosis, a small B-cell clone, most commonly a plasma cell
clone, produces monoclonal light chains that exert organ toxicity and deposit in tissue in the …

Several effective chemotherapy regimens have been developed during the last decade
significantly improving the outlook of patients with AL amyloidosis. Drs. Palladini and Merlini …

The combination of cyclophosphamide/bortezomib/dexamethasone (CyBorD) showed early
promise of high rates of hematologic responses tempered by studies showing the inability to …

Background This guideline has been developed jointly by the European Society of
Haematology and International Society of Amyloidosis recommending non-transplant …

High‐dose melphalan and stem cell transplantation (HDM/SCT) is an effective treatment for
selected patients with AL amyloidosis. We report the long‐term outcomes of 648 patients …

Immune-modulatory drugs are active in immunoglobulin light-chain amyloidosis and the
addition of alkylating agents can potentiate their action. In this phase II prospective trial we …

Previous studies have suggested that, in patients with AL amyloidosis treated with high-dose
melphalan and autologous stem-cell transplantation (HDM/SCT), the greatest benefit is seen …

A prospective randomized trial was conducted to study the timing of high-dose intravenous
melphalan and autologous stem cell transplantation (HDM/SCT) in AL amyloidosis. In all …

The treatment of patients with systemic light chain (AL) amyloidosis is a challenge to
hematologists. Despite its generally small size, the underlying clone causes a rapidly …